Interpretation of updated key points in the American Diabetes Association’s 2025 Standards of Care in Diabetes

Dong Xiaoying, Yin Jingxia, Li Ling, Yu Li, Pu Danlan, Liao Yong

PDF(2172 KB)
PDF(2172 KB)
Journal of Chongqing Medical University ›› 2025, Vol. 50 ›› Issue (05) : 565-573. DOI: 10.13406/j.cnki.cyxb.003750
Endocrine Regulation and Metabolic Diseases

Interpretation of updated key points in the American Diabetes Association’s 2025 Standards of Care in Diabetes

Author information +
History +

Abstract

Over the years，the American Diabetes Association（ADA） has been actively committed to the development and promotion of standards for the diagnosis，treatment，and daily care of diabetes. Since 1989，it has updated the diabetes diagnosis and treatment standards every year，which have become one of the most authoritative guidelines in diabetes and have been recognized and adopted by various countries. On December 10，2024，the 2025 Standards of Care in Diabetes were released，incorporating the latest evidence-based medicine content related to diabetes and its complications and comorbidities. It aims to provide guidance on the diagnosis，treatment，and management of the condition for clinicians，patients and their families，and researchers. This article interprets the major updates from the Standards.

Key words

diabetes mellitus / guideline / American Diabetes Association / diagnosis / treatment / management

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
Dong Xiaoying , Yin Jingxia , Li Ling , et al . Interpretation of updated key points in the American Diabetes Association’s 2025 Standards of Care in Diabetes. Journal of Chongqing Medical University. 2025, 50(05): 565-573 https://doi.org/10.13406/j.cnki.cyxb.003750

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis
1
Sacks DB， Arnold M， Bakris GL，et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus[J]. Clin Chem，2023，69（8）：808-868.
本文引用 [1]
2
Eckhardt BJ， Holzman RS， Kwan CK，et al. Glycated hemoglobin a（1c） as screening for diabetes mellitus in HIV-infected individuals[J]. AIDS Patient Care STDS，2012，26（4）：197-201.
3
Kim PS， Woods C， Georgoff P，et al. A1C underestimates glycemia in HIV infection[J]. Diabetes Care，2009，32（9）：1591-1593.
本文引用 [1]
4
Holt RIG， DeVries JH， Hess-Fischl A，et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association（ADA） and the European Association for the Study of Diabetes（EASD）[J]. Diabetologia，2021，64（12）：2609-2652.
本文引用 [1]
5
Khader YS， Dauod AS， El-Qaderi SS，et al. Periodontal status of diabetics compared with nondiabetics：a meta-analysis[J]. J Diabetes Complications，2006，20（1）：59-68.
本文引用 [1]
6
Casanova L， Hughes FJ， Preshaw PM. Diabetes and periodontal disease：a two-way relationship[J]. Br Dent J，2014，217（8）：433-437.
7
Eke PI， Thornton-Evans GO， Wei L，et al. Periodontitis in US adults：national health and nutrition examination survey 2009-2014[J]. J Am Dent Assoc，2018，149（7）：576-588.
本文引用 [1]
8
Kouidrat Y， Pizzol D， Cosco T，et al. High prevalence of erectile dysfunction in diabetes：a systematic review and meta-analysis of 145 studies[J]. Diabet Med，2017，34（9）：1185-1192.
本文引用 [1]
9
Broos B， Charleer S， Bolsens N，et al. Diabetes knowledge and metabolic control in type 1 diabetes starting with continuous glucose monitoring：future-PEAK[J]. J Clin Endocrinol Metab，2021，106（8）：e3037-e3048.
本文引用 [1]
10
Yoo JH， Kim G， Lee HJ，et al. Effect of structured individualized education on continuous glucose monitoring use in poorly controlled patients with type 1 diabetes：a randomized controlled trial[J]. Diabetes Res Clin Pract，2022，184：109209.
本文引用 [1]
11
Rubino F， Batterham RL， Koch M，et al. Lancet diabetes & endocrinology commission on the definition and diagnosis of clinical obesity[J]. Lancet Diabetes Endocrinol，2023，11（4）：226-228.
本文引用 [1]
12
Klein S， Gastaldelli A， Yki-Järvinen H，et al. Why does obesity cause diabetes?[J]. Cell Metab，2022，34（1）：11-20.
本文引用 [1]
13
Holt RIG， DeVries JH， Hess-Fischl A，et al. The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association（ADA） and the European Association for the Study of Diabetes（EASD）[J]. Diabetes Care，2021，44（11）：2589-2625.
本文引用 [1]
14
Mulinacci G， Todd Alonso G， Snell-Bergeon JK，et al. Glycemic outcomes with early initiation of continuous glucose monitoring system in recently diagnosed patients with type 1 diabetes[J]. Diabetes Technol Ther，2019，21（1）：6-10.
本文引用 [1]
15
Elbalshy M， Haszard J， Smith H，et al. Effect of divergent continuous glucose monitoring technologies on glycaemic control in type 1 diabetes mellitus：a systematic review and meta-analysis of randomised controlled trials[J]. Diabet Med，2022，39（8）：e14854.
16
Champakanath A， Akturk HK， Alonso GT，et al. Continuous glucose monitoring initiation within first year of type 1 diabetes diagnosis is associated with improved glycemic outcomes：7-year follow-up study[J]. Diabetes Care，2022，45（3）：750-753.
17
Weinstock RS， Xing DY， Maahs DM，et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes：results from the T1D Exchange clinic registry[J]. J Clin Endocrinol Metab，2013，98（8）：3411-3419.
18
Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group， Tamborlane WV， Beck RW，et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes[J]. N Engl J Med，2008，359（14）：1464-1476.
19
Polonsky WH， Hessler D， Ruedy KJ，et al. The impact of continuous glucose monitoring on markers of quality of life in adults with type 1 diabetes：further findings from the DIAMOND randomized clinical trial[J]. Diabetes Care，2017，40（6）：736-741.
本文引用 [1]
20
Garg SK， Kaur G， Haider Z，et al. Efficacy of semaglutide in overweight and obese patients with type 1 diabetes[J]. Diabetes Technol Ther，2024，26（3）：184-189.
本文引用 [1]
21
Garg SK， Akturk HK， Kaur G，et al. Efficacy and safety of tirzepatide in overweight and obese adult patients with type 1 diabetes[J]. Diabetes Technol Ther，2024，26（6）：367-374.
本文引用 [1]
22
Type 1 diabetes impacts of semaglutide on cardiovascular outcomes（T 1-DISCO） [EB/OL].（2024-11-28）[2025-01-24].
https:// clinicaltrials.gov/study/NCT05819138?tab=results
本文引用 [1]
23
ADJUnct semaglutide treatment in type 1 diabetes（ADJUST-T 1D） [EB/OL].（2024-08-27）[2025-01-24].
https://clinicaltrials.gov/study/NCT05537233
本文引用 [1]
24
Mills KT， Chen J， Yang W，et al. Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease[J]. Jama，2016，315（20）：2200.
本文引用 [1]
25
Whelton PK， Carey RM， Aronow WS，et al.2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention，detection，evaluation，and management of high blood pressure in adults：executive summary：a report of the American college of cardiology/American heart association task force on clinical practice guidelines[J]. Hypertension，2018，71（6）：1269-1324.
本文引用 [1]
26
U.S. Department of Health and Human Services. Physical Activity Guidelines for Americans，2nd edition，2018[EB/OL].（2024-08-12）[2025-01-24].
https://health.gov/sites/default/files/2019-09/Physical_Activity_Guidelines_2nd_ edition.pdf
本文引用 [1]

Comments

PDF(2172 KB)

Accesses

Citation

Detail
Sections
Recommended
Copyright © Journal of Chongqing Medical University, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉